Faron Pharmaceuticals Oy (LON:FARN) was up 1.8% on Monday . The stock traded as high as GBX 295 ($3.88) and last traded at GBX 277.50 ($3.65), approximately 70,366 shares changed hands during trading. An increase of 385% from the average daily volume of 14,501 shares. The stock had previously closed at GBX 272.50 ($3.58).

The firm has a market cap of $116.89 million and a PE ratio of -2.52. The firm has a fifty day simple moving average of GBX 267.19 and a two-hundred day simple moving average of GBX 162.17. The company has a debt-to-equity ratio of 577.78, a quick ratio of 0.64 and a current ratio of 0.88.

About Faron Pharmaceuticals Oy (LON:FARN)

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute organ traumas, vascular damage, and cancer immunotherapy. The company's lead product candidate is Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS).

Featured Article: How to calculate the annual rate of depreciation

Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.